Literature DB >> 27321581

Serum inflammatory profiles in pulmonary tuberculosis and their association with treatment response.

Rihwa Choi1, Kyunga Kim2, Min-Ji Kim3, Su-Young Kim4, O Jung Kwon5, Kyeongman Jeon6, Hye Yun Park7, Byeong-Ho Jeong8, Sung Jae Shin9, Won-Jung Koh10, Soo-Youn Lee11.   

Abstract

The aim of this study was to evaluate serum cytokines and natural antimicrobial peptide profiles in pulmonary tuberculosis, and compare them with levels in controls without tuberculosis, to explore the associations between these biomarkers and response to antituberculosis treatment. Serum levels of 10 biomarkers were measured using a Luminex bead array platform. Tuberculosis biosignatures were identified from the discovery cohort (n=148) and were validated in the independent cohort (n=148). Association between biosignatures and clinical outcome was investigated with negative conversion in follow-up sputum culture after 2months of treatment. Serum concentrations of eotaxin, MIP-1α, sIL-2Rα, and lipocalin 2 were significantly different between pulmonary tuberculosis patients and controls (P<0.05). Serum concentrations of eotaxin and sIL-2Rα were higher in pulmonary tuberculosis patients than in controls, while those of MIP-1α and lipocalin 2 were lower (P<0.05). Eotaxin concentrations were significantly higher in good responders to treatment (P<0.05), indicating this immunomolecule may serve as a positive predictor for therapy response in pulmonary tuberculosis. The magnitude serum eotaxin, MIP-1α, sIL-2Rα, and lipocalin 2 are important indicators for pulmonary tuberculosis. These biomarkers alone or combinatorial detections have potential applicability in monitoring tuberculosis patients during antituberculosis treatment. SIGNIFICANCE: Cytokines and endogenous antimicrobial peptides represent an important part of immune system and the identification of a pattern of differentially expressed those biomarkers (a "biosignature") could help to differentiate tuberculosis infection from the non-infected state which might eventually assist case identification and accelerate access to treatment. In this direction, cytokine analysis including multiple serum biomarkers to evaluate biosignatures of pulmonary tuberculosis would provide basic knowledge to aid understanding of the pathophysiology of tuberculosis infection and for the development of future diagnostic methods, treatments, and monitoring for pulmonary tuberculosis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antituberculosis treatment; Biomarker; Immunomolecule; Serum; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27321581     DOI: 10.1016/j.jprot.2016.06.016

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  9 in total

1.  Bead Based Multiplex Assay for Analysis of Tear Cytokine Profiles.

Authors:  Praveen Kumar Balne; Veonice Bijin Au; Louis Tong; Arkasubhra Ghosh; Mukesh Agrawal; John Connolly; Rupesh Agrawal
Journal:  J Vis Exp       Date:  2017-10-13       Impact factor: 1.355

2.  Plasma cytokine levels characterize disease pathogenesis and treatment response in tuberculosis patients.

Authors:  Monika M Vivekanandan; Ernest Adankwah; Wilfred Aniagyei; Isaac Acheampong; Augustine Yeboah; Joseph F Arthur; Millicent N K Lamptey; Mohammed K Abass; Amidu Gawusu; Francis Kumbel; Francis Osei-Yeboah; Linda Batsa Debrah; Dorcas O Owusu; Alexander Debrah; Ertan Mayatepek; Julia Seyfarth; Richard O Phillips; Marc Jacobsen
Journal:  Infection       Date:  2022-06-27       Impact factor: 3.553

Review 3.  Omics Biomarkers for Monitoring Tuberculosis Treatment: A Mini-Review of Recent Insights and Future Approaches.

Authors:  Dian Ayu Eka Pitaloka; Mas Rizky Anggun A A Syamsunarno; Rizky Abdulah; Lidya Chaidir
Journal:  Infect Drug Resist       Date:  2022-05-28       Impact factor: 4.177

4.  Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response.

Authors:  Karen Cilliers; Angela Menezes; Tariq Webber; Hazel M Dockrell; Jacqueline M Cliff; Léanie Kleynhans; Novel N Chegou; Nelita du Plessis; André G Loxton; Martin Kidd; Joel Fleury Djoba Siawaya; Katharina Ronacher; Gerhard Walzl
Journal:  Tuberculosis (Edinb)       Date:  2021-04-10       Impact factor: 3.131

5.  Lipocalin-2 Functions as Inhibitor of Innate Resistance to Mycobacterium tuberculosis.

Authors:  Sara Louise Dahl; Joshua S Woodworth; Christian Johann Lerche; Elisabeth Præstekjær Cramer; Pia Rude Nielsen; Claus Moser; Allan Randrup Thomsen; Niels Borregaard; Jack Bernard Cowland
Journal:  Front Immunol       Date:  2018-11-26       Impact factor: 7.561

6.  The mRNA expression of visfatin and lipocalin-2 in peripheral blood mononuclear cells from patients with pulmonary tuberculosis.

Authors:  Hong-Miao Li; Qian Huang; Shuang-Shuang Chen; Gen-You Zhang; Si-Jiu Shi; Ye Li; Tian-Ping Zhang
Journal:  J Clin Lab Anal       Date:  2020-07-18       Impact factor: 2.352

7.  Biomarkers That Correlate with Active Pulmonary Tuberculosis Treatment Response: a Systematic Review and Meta-analysis.

Authors:  Claudia M Denkinger; Mikashmi Kohli; Alexandra J Zimmer; Federica Lainati; Nathaly Aguilera Vasquez; Carole Chedid; Sean McGrath; Andrea Benedetti; Emily MacLean; Morten Ruhwald
Journal:  J Clin Microbiol       Date:  2021-12-15       Impact factor: 5.948

8.  Identification of plasma biomarkers for discrimination between tuberculosis infection/disease and pulmonary non tuberculosis disease.

Authors:  Marco Pio La Manna; Valentina Orlando; Paolo Li Donni; Guido Sireci; Paola Di Carlo; Antonio Cascio; Francesco Dieli; Nadia Caccamo
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240

9.  High sensitivity and specificity of a 5-analyte protein and microRNA biosignature for identification of active tuberculosis.

Authors:  Jessica L Pedersen; Simone E Barry; Nilesh J Bokil; Magda Ellis; YuRong Yang; Guangyu Guan; Xiaolin Wang; Alen Faiz; Warwick J Britton; Bernadette M Saunders
Journal:  Clin Transl Immunology       Date:  2021-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.